Prolonged Cefepime-Induced Neurotoxicity in a Patient with End-Stage Renal Disease
- PMID: 35067669
- PMCID: PMC8800466
- DOI: 10.12659/AJCR.934083
Prolonged Cefepime-Induced Neurotoxicity in a Patient with End-Stage Renal Disease
Abstract
BACKGROUND Cefepime, a fourth-generation cephalosporin, has a known adverse effect of neurotoxicity. It occurs notably in patients with end-stage renal disease, but symptom resolution typically occurs within a median of 2 days following drug discontinuation. CASE REPORT We present a patient with end-stage renal disease on hemodialysis (TWThSat) who developed prolonged neurotoxicity lasting longer than 1 week complicated by nonconvulsive status epilepticus 2 days after cefepime discontinuation. She presented initially with a right upper-extremity arteriovenous graft infection from extended-spectrum beta-lactamase Escherichia coli, and was treated with cefepime. She eventually developed acute encephalopathy, and cefepime was discontinued. However, 2 days later, she developed seizures with worsened mental status. She was stabilized on levetiracetam and lorazepam, but developed hypotension in the Neurological Intensive Care Unit (Neuro-ICU), delaying hemodialysis. Hemodialysis was performed 6 days after cefepime discontinuation once she was stabilized, and her mental status improved 1 to 2 days after, with full improvement 20 days after admission. She was discharged on levetiracetam and meropenem. In addition, we review risk factors and symptomology of cefepime-induced neurotoxicity and discuss important management issues. CONCLUSIONS Careful attention should be paid when administering cefepime to patients with end-stage renal disease. Patients showing signs of encephalopathy should not be on cefepime any longer, and more aggressive measures may be taken, such as prompt hemodialysis, assessment of cefepime blood levels, and electroencephalogram (EEG) to monitor for signs of seizures. Prolonging hemodialysis in patients with signs of cefepime neurotoxicity can pose a danger for more serious sequelae, such as status epilepticus. Close monitoring of patients at high risk of developing adverse events from cefepime administration can ensure patient safety and well-being.
Conflict of interest statement
Similar articles
-
Cefepime Neurotoxicity in Patients With Normal Renal Function: An Overlooked Cause of Encephalopathy in the Intensive Care Unit.J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241259534. doi: 10.1177/23247096241259534. J Investig Med High Impact Case Rep. 2024. PMID: 39068595 Free PMC article.
-
Cefepime-Induced Neurotoxicity Presenting with Nonconvulsive Status Epilepticus Admitted as a Stroke Alert.Am J Case Rep. 2020 Mar 9;21:e921643. doi: 10.12659/AJCR.921643. Am J Case Rep. 2020. PMID: 32147665 Free PMC article.
-
Cefepime neurotoxicity despite renal adjusted dosing.Scand J Infect Dis. 2011 Oct;43(10):827-9. doi: 10.3109/00365548.2011.581308. Epub 2011 May 23. Scand J Infect Dis. 2011. PMID: 21604923
-
Cefepime-induced nonconvulsive status epilepticus: case report and review.Neurocrit Care. 2009;10(3):347-51. doi: 10.1007/s12028-008-9166-8. Epub 2008 Nov 25. Neurocrit Care. 2009. PMID: 19034700 Review.
-
Cefepime Induced Neurotoxicity Mimicking Clinical Presentation of Left Middle Cerebral Artery Infarction: A Case Report and Review of Literature.Acta Neurol Taiwan. 2022 Jan 25;31(1):41-45. Acta Neurol Taiwan. 2022. PMID: 34988953 Review.
Cited by
-
The Trend of Cefepime-Induced Neurotoxicity: A Systematic Review.Cureus. 2023 Jun 26;15(6):e40980. doi: 10.7759/cureus.40980. eCollection 2023 Jun. Cureus. 2023. PMID: 37503476 Free PMC article. Review.
-
Cefepime-induced neurotoxicity.S Afr J Infect Dis. 2025 Apr 30;40(1):704. doi: 10.4102/sajid.v40i1.704. eCollection 2025. S Afr J Infect Dis. 2025. PMID: 40357178 Free PMC article.
-
Role of the gut microbiota in cefoperazone/sulbactam-induced epilepsy in mice with chronic renal failure.Ren Fail. 2024 Dec;46(2):2371551. doi: 10.1080/0886022X.2024.2371551. Epub 2024 Jun 28. Ren Fail. 2024. PMID: 38938213 Free PMC article.
-
Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia.Antibiotics (Basel). 2023 May 30;12(6):984. doi: 10.3390/antibiotics12060984. Antibiotics (Basel). 2023. PMID: 37370303 Free PMC article.
-
Cefepime Neurotoxicity in Patients With Normal Renal Function: An Overlooked Cause of Encephalopathy in the Intensive Care Unit.J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241259534. doi: 10.1177/23247096241259534. J Investig Med High Impact Case Rep. 2024. PMID: 39068595 Free PMC article.
References
-
- Li HT, Lee CH, Wu T, et al. Clinical, electroencephalographic features and prognostic factors of cefepime-induced neurotoxicity: A retrospective study. Neurocrit Care. 2019;31(2):329–37. - PubMed
-
- Deshayes S, Coquerel A, Verdon R. Neurological adverse effects attributable to β-lactam antibiotics: A literature review. Drug Safety. 2017;40(12):1171–98. - PubMed
-
- Boschung-Pasquier L, Atkinson A, Kastner LK, et al. Cefepime neurotoxicity: Thresholds and risk factors. A retrospective cohort study. Clin Microbiol Infect. 2020;26(3):333–39. - PubMed
-
- Nakagawa R, Sato K, Uesaka Y, et al. Cefepime-induced encephalopathy in end-stage renal disease patients. J Neurol Sci. 2017;376:123–28. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical